Branded Legacy, Inc. Expands into Biotech and Medical Devices with Acquisition of Bio Legacy Evaluative Group
TL;DR
Branded Legacy's acquisition of Bio Legacy Evaluative Group for $1.5 million in Preferred D shares positions it to capitalize on the growing $1.16 billion intranasal naloxone market by 2032.
The all-stock deal includes performance-based conversion milestones, a two-year lock-up, and a $1 million R&D commitment post-uplisting to OTCQB, enhancing Branded Legacy's biotech portfolio.
This acquisition enables Branded Legacy to tackle global health issues like the addiction epidemic and vaccine distribution inefficiencies, improving public health outcomes worldwide.
Branded Legacy now owns a patented intranasal naloxone device and nasal delivery technology for vaccines, marking a significant leap in health and wellness innovation.
Found this article helpful?
Share it with your network and spread the knowledge!
Branded Legacy, Inc. (OTC: BLEG), a diversified holdings company known for its focus on the health and wellness sector, has officially expanded its portfolio into the biotech and medical devices industry through the acquisition of Bio Legacy Evaluative Group. This strategic move, finalized on July 31, 2025, was executed through an all-stock deal valued at $1.5 million in Preferred D shares. The acquisition not only signifies Branded Legacy's commitment to addressing pressing global health issues but also positions the company at the forefront of innovative solutions for the addiction epidemic and vaccine distribution inefficiencies.
Under the leadership of CEO Amin Janmohamed, Bio Legacy Evaluative Group brings to the table a patented all-in-one intranasal naloxone device. This device is designed to combat the opioid crisis, tapping into a market that is projected to grow significantly from $371 million in 2022 to over $1.16 billion by 2032. Additionally, Bio Legacy's technology for nasal delivery of vaccines and cold-chain therapies presents a promising avenue for improving vaccine distribution and accessibility worldwide.
The terms of the acquisition include performance-based conversion milestones, a two-year lock-up period, and a commitment of $1 million towards research and development following the company's uplisting to OTCQB. This investment underscores Branded Legacy's dedication to innovation and its strategic vision for growth in the biotech sector. For more details on the acquisition, visit https://ibn.fm/U7eSy.
Branded Legacy's expansion into biotech and medical devices through this acquisition is a testament to the company's forward-thinking approach and its commitment to enhancing lives through innovative health solutions. With a strong foundation in the health and wellness sector, Branded Legacy is well-positioned to make significant contributions to the biotech industry, offering sustainable value to its shareholders and making a positive impact on global health challenges. For more information about Branded Legacy, visit https://BrandedLegacy.com.
Curated from InvestorBrandNetwork (IBN)
